Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres.

Jin-Kyoung ShimSeonah ChoiSeon-Jin YoonRan Joo ChoiJunseong ParkEun Hee LeeHye Joung ChoSuji LeeWan-Yee TeoJu Hyung MoonHyun Sil Kim Kyung Hwan Kim Jae Ho Cheong Jong Hee Chang Jong-In Yook Seok-Gu Kang

Published in: Cancer cell international (2022)

ETO, an FAO inhibitor, causes a lethal energy reduction in the GBM TSs. When used in combination with TMZ, ETO effectively reduces GBM cell stemness and invasiveness and further improves survival. These results suggest a potential novel treatment option for GBM.

Keyphrases

stem cells
epithelial mesenchymal transition
single cell
cell therapy
cancer stem cells
free survival
newly diagnosed
human health
bone marrow